MediciNova, Inc. (MNOV): Price and Financial Metrics


MediciNova, Inc. (MNOV): $2.31

-0.12 (-4.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNOV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNOV POWR Grades


  • MNOV scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.7% of US stocks.
  • MNOV's strongest trending metric is Growth; it's been moving down over the last 131 days.
  • MNOV ranks lowest in Momentum; there it ranks in the 10th percentile.

MNOV Stock Summary

  • For MNOV, its debt to operating expenses ratio is greater than that reported by merely 5.65% of US equities we're observing.
  • MNOV's price/sales ratio is 31.82; that's higher than the P/S ratio of 94.77% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.05 for Medicinova Inc; that's greater than it is for only 6.17% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Medicinova Inc are EYEN, TARS, FOLD, PXLW, and CRDF.
  • MNOV's SEC filings can be seen here. And to visit Medicinova Inc's official web site, go to medicinova.com.

MNOV Valuation Summary

  • In comparison to the median Healthcare stock, MNOV's price/sales ratio is 322.03% higher, now standing at 47.9.
  • Over the past 179 months, MNOV's price/sales ratio has gone down 67.3.
  • MNOV's EV/EBIT ratio has moved down 7.4 over the prior 179 months.

Below are key valuation metrics over time for MNOV.

Stock Date P/S P/B P/E EV/EBIT
MNOV 2021-08-31 47.9 2.1 -17.2 -10.2
MNOV 2021-08-30 46.8 2.1 -16.8 -9.8
MNOV 2021-08-27 46.6 2.1 -16.7 -9.7
MNOV 2021-08-26 46.8 2.1 -16.8 -9.8
MNOV 2021-08-25 46.3 2.1 -16.6 -9.6
MNOV 2021-08-24 45.2 2.0 -16.2 -9.2

MNOV Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at -9.45%.
  • The 4 year price growth rate now stands at -26.1%.
  • Its 3 year cash and equivalents growth rate is now at 128.87%.
Over the past 34 months, MNOV's revenue has gone up $4,037,500.

The table below shows MNOV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 4.0375 -9.381605 -10.13425
2021-09-30 4.0375 -7.691724 -11.0364
2021-06-30 4 -8.584199 -11.16105
2021-03-31 4 -11.80169 -11.32814
2020-12-31 0 -10.82636 -13.8539
2020-09-30 0 -11.28166 -12.8527

MNOV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNOV has a Quality Grade of D, ranking ahead of 17.27% of graded US stocks.
  • MNOV's asset turnover comes in at 0.047 -- ranking 325th of 680 Pharmaceutical Products stocks.
  • ACER, SCYX, and ATNM are the stocks whose asset turnover ratios are most correlated with MNOV.

The table below shows MNOV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.047 1 -2.232
2021-03-31 0.049 1 -2.359
2020-12-31 0.000 NA -3.663
2020-09-30 0.000 NA -3.396
2020-06-30 0.000 NA -3.088
2020-03-31 0.000 NA -2.751

MNOV Price Target

For more insight on analysts targets of MNOV, see our MNOV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.33 (Strong Buy)

MNOV Stock Price Chart Interactive Chart >

Price chart for MNOV

MNOV Price/Volume Stats

Current price $2.31 52-week high $5.09
Prev. close $2.43 52-week low $2.09
Day low $2.31 Volume 23,900
Day high $2.46 Avg. volume 82,740
50-day MA $2.64 Dividend yield N/A
200-day MA $3.06 Market Cap 113.29M

MediciNova, Inc. (MNOV) Company Bio


MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. The company was founded in 2000 and is based in La Jolla, California.


MNOV Latest News Stream


Event/Time News Detail
Loading, please wait...

MNOV Latest Social Stream


Loading social stream, please wait...

View Full MNOV Social Stream

Latest MNOV News From Around the Web

Below are the latest news stories about Medicinova Inc that investors may wish to consider to help them evaluate MNOV as an investment opportunity.

MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs

LA JOLLA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced MN-166 (ibudilast) was discussed as one of the promising pharmacological agents for the treatment of alcohol use disorder (AUD) in the journal Drugs. The publication entitled “Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder,” co-authored by Me

Yahoo | February 22, 2022

The past three years for MediciNova (NASDAQ:MNOV) investors has not been profitable

Investing in stocks inevitably means buying into some companies that perform poorly. Long term MediciNova, Inc...

Yahoo | February 14, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Rise and shine, trader!

William White on InvestorPlace | February 1, 2022

MediciNova nabs new patent in Korea for MN-001 for treatment of blood cholesterol

MediciNova (MNOV) received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia,

Seeking Alpha | February 1, 2022

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea

LA JOLLA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a new patent from the Korean Intellectual Property Office which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent appli

Yahoo | February 1, 2022

Read More 'MNOV' Stories Here

MNOV Price Returns

1-mo -26.20%
3-mo -4.94%
6-mo -28.04%
1-year -45.13%
3-year -78.23%
5-year -58.08%
YTD -13.81%
2021 -49.05%
2020 -21.96%
2019 -17.50%
2018 26.28%
2017 7.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4865 seconds.